Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study.
OBJECTIVE
The optimal adrenergic support in shock is controversial. We investigated whether dopamine administration influences the outcome from shock.


METHODS
Cohort, multiple-center, observational study.


METHODS
One hundred and ninety-eight European intensive care units.


METHODS
All adult patients admitted to a participating intensive care unit between May 1 and May 15, 2002.


METHODS
None.


RESULTS
Patients were followed up until death, until hospital discharge, or for 60 days. Shock was defined as hemodynamic compromise necessitating the administration of vasopressor catecholamines. Of 3,147 patients, 1,058 (33.6%) had shock at any time; 462 (14.7%) had septic shock. The intensive care unit mortality rate for shock was 38.3% and 47.4% for septic shock. Of patients in shock, 375 (35.4%) received dopamine (dopamine group) and 683 (64.6%) never received dopamine. Age, gender, Simplified Acute Physiology Score II, and Sequential Organ Failure Assessment score were comparable between the two groups. The dopamine group had higher intensive care unit (42.9% vs. 35.7%, p=.02) and hospital (49.9% vs. 41.7%, p=.01) mortality rates. A Kaplan-Meier survival curve showed diminished 30 day-survival in the dopamine group (log rank=4.6, p=.032). In a multivariate analysis with intensive care unit outcome as the dependent factor, age, cancer, medical admissions, higher mean Sequential Organ Failure Assessment score, higher mean fluid balance, and dopamine administration were independent risk factors for intensive care unit mortality in patients with shock.


CONCLUSIONS
This observational study suggests that dopamine administration may be associated with increased mortality rates in shock. There is a need for a prospective study comparing dopamine with other catecholamines in the management of circulatory shock.
Sakr
Yasser
Y
Department of Intensive Care, Erasme Hospital, Free University of Brussels, Belgium.
Reinhart
Konrad
K
Vincent
Jean-Louis
JL
Sprung
Charles L
CL
Moreno
Rui
R
Ranieri
V Marco
VM
De Backer
Daniel
D
Payen
Didier
D
D000368:Aged; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002395:Catecholamines / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use*; D005060:Europe / Q000453:epidemiology; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D007362:Intensive Care Units; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009638:Norepinephrine / Q000627:therapeutic use; D011446:Prospective Studies; D012307:Risk Factors; D012769:Shock / Q000188:drug therapy* / Q000401:mortality; D012772:Shock, Septic / Q000188:drug therapy / Q000401:mortality; D015996:Survival Rate
D002316:Cardiotonic Agents; D002395:Catecholamines; D004298:Dopamine; D009638:Norepinephrine